Clinical Scorecard: Integrating Digital Pathology and AI in Breast and Gynecologic Cancer: From Molecular Insights to Multimodal Approaches

At a Glance

Key Highlights

• Digital pathology has evolved from archival use to a quantitative platform enabling AI-driven analysis of morphologic features linked to genomics and prognosis.
• Molecular classification frameworks (e.g., hormone receptor status, HER2, mismatch repair, POLE mutations, TP53, BRCA1/2, HPV pathways) guide risk stratification and treatment.
• AI models, including deep learning and foundation models, can predict molecular alterations, treatment response, and outcomes by analyzing complex histopathologic patterns.

Guideline-Based Recommendations

Diagnosis

• Incorporate integrated molecular testing (e.g., hormone receptors, HER2, mismatch repair, POLE, TP53, BRCA1/2, HPV status) alongside histopathology for accurate tumor classification.
• Utilize FDA-approved whole-slide imaging systems for primary diagnosis to enable digital pathology workflows.
• Apply AI and machine learning tools to enhance detection of subtle morphologic patterns and predict molecular alterations.

Management

• Use combined molecular and image-based data to guide personalized treatment decisions and risk stratification in breast and gynecologic cancers.
• Adopt multimodal approaches integrating spatial transcriptomics and proteomics to understand tumor heterogeneity and microenvironment interactions.

Monitoring & Follow-up

• Implement digital pathology and AI tools to monitor treatment response and disease progression through quantitative image analysis.
• Ensure reproducibility and standardization in digital workflows to maintain consistent monitoring across institutions.

Risks

• Address challenges including increased costs, tissue requirements, longer turnaround times, and workflow fragmentation associated with molecular testing.
• Mitigate variability due to differences in scanners, staining protocols, and institutional practices to ensure reliable AI model performance.
• Navigate regulatory and standardization hurdles to facilitate clinical adoption of multimodal digital pathology approaches.

Patient & Prescribing Data

Patients diagnosed with breast, endometrial, ovarian, and cervical cancers undergoing molecular and digital pathology evaluation

Molecular and AI-integrated pathology data inform targeted therapies, prognostic assessments, and personalized treatment planning.

Clinical Best Practices

• Integrate morphological, immunophenotypic, and molecular data at the point of care for holistic patient management.
• Leverage FDA-approved digital pathology platforms to enable AI-driven diagnostic workflows.
• Employ foundation AI models pretrained on large histopathology datasets to improve diagnostic accuracy and generalizability.
• Prioritize standardization, reproducibility, and workflow integration to optimize clinical utility of multimodal data.
• Foster multidisciplinary collaboration to interpret complex data layers for treatment decision-making.

References

• FDA approval of whole-slide imaging systems for primary diagnosis
• Campanella et al. real-world deployment of AI in pathology